3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Classical hematology
1
Conditions
Anemia
2
Pancreatic Neoplasms
1
Neoplasms
1
Lymphoproliferative Disorders
1
Liver Neoplasms
1
Inflammatory Breast Neoplasms
1
Carcinoma, Ductal, Breast
1
Cancer Anaemia
1
Aortic Aneurysm
1
Anemia, Iron-Deficiency
1
Advanced Gastric Carcinoma
1
Interventions
Rituximab
2
Epoetin Alfa
2
Early Intervention, Educational
2
Dexamethasone
2
Darbepoetin alfa
2
Bortezomib
2
ponatinib
1
pegaspargase
1
isatuximab
1
ibrutinib
1
ibritumomab tiuxetan
1
ferrous sulfate
1
ferric gluconate
1
ferric carboxymaltose
1
cirmtuzumab
1
blinatumomab
1
asparaginase erwinia chrysanthemi recombinant
1
acalabrutinib
1
Vorinostat
1
Vincristine
1
Sucrose
1
Prednisone
1
Methotrexate
1
Melphalan
1
Lenalidomide
1
Imatinib Mesylate
1
Ifosfamide
1
Etoposide
1
Doxorubicin
1
Daunorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoproliferative Disorders
×
ferric carboxymaltose
×
Clear all
NCT01101399
2013-12-18
FID-CHEMO
Vifor Pharma
Phase 3
Completed
19 enrolled